Skip to main content
Clinical Trials/NCT00330954
NCT00330954CompletedNot Applicable

Gene Expression Profiling in Type 1 Diabetes

Children's Mercy Hospital Kansas City1 site in 1 country64 target enrollmentStarted: June 2006Last updated:
Conditions

Trial Snapshot

Phase
Not Applicable
Status
Completed
Sponsor
Enrollment
64
Locations
1

Study Overview

Brief Summary

One of the goals of the Kansas City Diabetes Consortium is to identify and characterize genes and their products that are associated with T1DM. Characterization of such genes and their products can aid in developing new tools for risk assessment, development of new prevention strategies and monitoring progression of disease.

Study design: Descriptive, basic science pilot study. The results of this pilot study will be used to help design a much larger study to address the importance of viral response and autoimmune diabetes.

Detailed Description

The hypothesis is that viral responsive genes are up-regulated prior to the onset of symptoms of Type 1 Diabetes (T1DM) and may correlate with increased expression of interferon alpha.

Both genetic and environmental factors contribute to risk of development of T1DM. There are a number of conflicting reports associating viral infections and T1DM in genetically susceptible individuals and causality has not been proven. Viruses may not have a large role in the initiation of islet cell autoimmunity but more of a role in acceleration of the disease leading to overt symptoms. There are no studies describing viral responsive gene expression in these individuals.

Study Design

Study Type
Observational
Observational Model
Case Control
Time Perspective
Prospective

Eligibility Criteria

Ages
7 Years to 14 Years (Child)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Male and female subjects 7-14 years of age
  • New onset T1DM
  • Five years post onset of T1DM
  • Participant in the TrialNet initiative and either antibody positive or antibody negative sibling control
  • Body weight sufficient to tolerate an additional 15ml (1 tbsp) blood loss

Exclusion Criteria

  • Subjects who do not meet the criteria above
  • Subjects who have received steroids or other immunosuppressive therapy within the 6 months prior to enrollment into the study

Investigators

Sponsor
Children's Mercy Hospital Kansas City
Sponsor Class
Other

Study Sites (1)

Loading locations...

Similar Trials

Gene Expression Profiling in Type 1... | Clinical Trial